Nanomedical Diagnostics, which declared the commercialization of a graphene biosensor in September 2015, announced the completion of a Series A financing round of $1.6 million. The funding round will enable the company to commercially release AGILE Research, its new label-free, quantitative, affordable research tool for small molecule and protein analysis. The company is also using the funds to lay the foundation for AGILE Lyme investigational product evaluation and market clearance.
Nanomedical Diagnostics states that it has achieved excellent progress in only 20 months, and that its current focus is finalizing AGILE Research product design. The company will be evaluating its performance with the CDC and Stanford University this fall and expects to launch the product early next year for commercial use to study proteins of interest.